|
PDE-5 inhibitor trials by condition (percent of total) |
|||
| Condition |
Sildenafil |
Tadalafil |
Vardenafil |
|
|
|||
| Mixed aetiology |
67 |
75 |
73 |
| Diabetes |
14 |
11 |
13 |
| Prostatectomy |
0.0 |
15 |
13 |
| Depression |
5.7 |
0.0 |
0.0 |
| Spinal cord injury |
5.3 |
0.0 |
0.0 |
| Multiple sclerosis |
3.1 |
0.0 |
0.0 |
| Coronary heart disease |
2.1 |
0.0 |
0.0 |
| Radiotherapy for prostate cancer |
1.7 |
0.0 |
0.0 |
| Renal failure and haemodialysis |
1.0 |
0.0 |
0.0 |
| Rectal surgery |
0.5 |
0.0 |
0.0 |
| Spina bifida |
0.5 |
0.0 |
0.0 |
Moore et al. BMC Urology 2005 5:18 doi:10.1186/1471-2490-5-18 |
|||